ADGIPS2
TEVA icon

AmericaFirst Defensive Growth & Income Portfolio Series 2’s Teva Pharmaceuticals TEVA Stock Holding History

AmericaFirst Defensive Growth & Income Portfolio Series 2’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$303K Buy
+9,110
New +$282K 0.38% 89

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AmericaFirst Defensive Growth & Income Portfolio Series 2's TEVA Position: Q2 2017 in Review

AmericaFirst Defensive Growth & Income Portfolio Series 2 opened a new position in Teva Pharmaceuticals (TEVA) in Q2 2017: 9,110 shares worth $303K. The stake represents 0.38% of the portfolio and ranks #89 among its holdings.

649 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

  • AmericaFirst Defensive Growth & Income Portfolio Series 2 held 9,110 shares of Teva Pharmaceuticals worth $303K as of Q2 2017.
  • Teva Pharmaceuticals was a new AmericaFirst Defensive Growth & Income Portfolio Series 2 position in Q2 2017.
  • Teva Pharmaceuticals made up 0.38% of AmericaFirst Defensive Growth & Income Portfolio Series 2's portfolio in Q2 2017, its #89 holding.
  • 649 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on AmericaFirst Defensive Growth & Income Portfolio Series 2's 13F filing for Q2 2017, filed 15 Aug 2017.